

ALLIA.143A

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Zaghouni) Group Art Unit 1644
)
 Appl. No. : 08/779,767)
)
 Filed : January 7, 1997)
)
 For : Compounds, Compositions and)
 Methods for the Endocytic)
 Presentation of Immunosuppressive)
 Factors)
 Examiner : P. Nolan)

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as Express Mail # EL879045042 US in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on

April 16, 2003

Nikki Weaver

Nikki Weaver

REQUEST FOR CONTINUED EXAMINATION

Commissioner for Patents
 Box RCE
 Washington, D.C. 20231

Dear Sir:

Applicant is hereby filing a Request for Continued Examination ("RCE"). Prosecution of the above entitled application is currently closed in that a final Office Action was received dated October 21, 2002. Applicant did file an amendment on December 19, 2002 (within two months of the date of the Office Action) in response to the Office Action. However, the wrong serial number was inadvertently added to the amendment (09/779,767 instead of 08/779,767) and apparently the amendment has not been received by the Examiner and thus has not been entered. Applicant is furnishing a copy of the response and postcard confirming that it was in fact filed and received by the Patent Office.

For this reason, Applicant is NOT filing the RCE with a three month extension of time in that an extension of time should not be required. However, applicant's attorney has authorized the payment of extension fees in the transmittal and in this Request for Continued Examination should payment of extension fees be determined as necessary to keep the application from becoming abandoned. Applicant has also authorized payment of the RCE fee.

01	1008
02	
03	
04	
05	
06	
07	
08	
09	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
61	
62	
63	
64	
65	
66	
67	
68	
69	
70	
71	
72	
73	
74	
75	
76	
77	
78	
79	
80	
81	
82	
83	
84	
85	
86	
87	
88	
89	
90	
91	
92	
93	
94	
95	
96	
97	
98	
99	
100	

04/29/2003 GDUCKETT 00000001 011008 08779767
 01 FC:2801 375.00 CR

#49/17
goiga
4-29-03

ALLIA.143A

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Zaghouni, H.) Group Art Unit 1644
Appl. No. : 09/779,767)
Filed : January 7, 1997)
For : Compounds, Compositions and)
Methods for the Endocytic)
Presentation of Immunosuppressive)
Factors)
Examiner : P. Nolan)

I hereby certify that this correspondence and
all marked attachments are being deposited
with the United States Postal Service as first
class mail in an envelope addressed to:
Commissioner of Patents and Trademarks,
Washington, D.C. 20231, on

12/19/2002
Christine Hughey
Christine Hughey

AMENDMENT AND RESPONSE TO OFFICE ACTION

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

In response to the Office Action dated October 21, 2002, applicant submits the following
response:

In the Claims:

Please amend claim 66 as follows:

#1
66. (Six times amended) A composition comprising an immunoglobulin or a portion thereof linked
to a protein fragment or peptide, wherein said immunoglobulin or portion thereof is capable of
binding to an Fc receptor and said protein fragment or peptide comprises a T cell receptor
antagonist, said composition having the property of being endocytosed by cells bearing said Fc
receptor and processed by the cells to present said T cell receptor antagonist in association with
endogenous MHC Class II molecules, thereby preventing activation of autoreactive T cells *in vivo*.